Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685266 | 1.00 | ROCK2 (0.46) | ROCK2MAP2K5MAPK7PTGESAURKA | |
| SCHEMBL29354347 | 1.00 | ROCK2 (0.46) | ROCK2MAP2K5MAPK7PTGESAURKA | |
| SCHEMBL16685268 | 1.00 | ROCK2 (0.46) | ROCK2MAP2K5MAPK7PTGESAURKA | |
| Trifluoroacetic Acid SCHEMBL2570194 | 0.95 | ROCK2 (0.42) | ROCK2MAP2K5MAPK7PTGESAURKA | |
| Trifluoroacetic Acid SCHEMBL2570197 | 0.95 | ROCK2 (0.42) | ROCK2MAP2K5MAPK7PTGESAURKA | |
| SCHEMBL30708649 | 0.94 | ACHE (0.41) | ROCK2PTGESPARP1PARP15PARP10 | |
| SCHEMBL3141992 | 0.93 | PTGES (0.40) | ROCK2PTGESKDM1ARCOR1KMT2A | |
| SCHEMBL3141983 | 0.93 | PTGES (0.40) | ROCK2PTGESKDM1ARCOR1KMT2A | |
| SCHEMBL30708650 | 0.92 | ROCK2 (0.39) | ROCK2MAP2K5MAPK7PTGESPARP1 | |
| SCHEMBL30708630 | 0.92 | ROCK2 (0.38) | ROCK2PTGESPARP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4308935-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321418-A | Cancer biomarkers and methods of use thereof | 诺华股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2914622-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015066432-A1 | METHOD OF TREATING POST-MYELOPROLIFERATIVE NEOPLASMS (MPNS) AND POST-MPN ACUTE MYELOID LEUKEMIA | FOUNDATION MEDICINE, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066439-A2 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES | FOUNDATION MEDICINE, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | ROCK2 1718/4885MAP2K5 4642/4885MAPK7 4578/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | ROCK2 1307/4885MAP2K5 4602/4885MAPK7 4450/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | ROCK2 1307/4885MAP2K5 4602/4885MAPK7 4450/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | ROCK2 1307/4885MAP2K5 4602/4885MAPK7 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.